Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of BL-M08D1 for advanced or metastatic melanoma and other solid tumors
CTR20263651Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Sep 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M08D1 in melanoma, Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
BL-M08D1
03
Conditions
melanomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20263651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263651.